GSA Capital Partners LLP Purchases Shares of 668,563 Cabaletta Bio, Inc. $CABA

GSA Capital Partners LLP acquired a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 668,563 shares of the company’s stock, valued at approximately $2,079,000.

Other large investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. boosted its position in shares of Cabaletta Bio by 142.9% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock worth $13,421,000 after acquiring an additional 5,195,285 shares during the last quarter. Millennium Management LLC increased its position in Cabaletta Bio by 298.5% during the fourth quarter. Millennium Management LLC now owns 2,736,912 shares of the company’s stock worth $5,994,000 after purchasing an additional 2,050,099 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Cabaletta Bio by 17.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company’s stock worth $21,590,000 after purchasing an additional 1,495,768 shares during the last quarter. Woodline Partners LP raised its stake in Cabaletta Bio by 75.2% during the third quarter. Woodline Partners LP now owns 2,135,348 shares of the company’s stock worth $4,997,000 after purchasing an additional 916,884 shares during the period. Finally, Ikarian Capital LLC purchased a new position in Cabaletta Bio during the fourth quarter worth approximately $1,971,000.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on CABA shares. Wall Street Zen cut shares of Cabaletta Bio from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Wells Fargo & Company reduced their target price on Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price objective on shares of Cabaletta Bio in a report on Monday, May 4th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Cabaletta Bio in a research note on Wednesday, June 3rd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cabaletta Bio presently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

Cabaletta Bio Stock Performance

Cabaletta Bio stock opened at $2.75 on Friday. The firm has a market capitalization of $448.39 million, a PE ratio of -1.75 and a beta of 3.30. Cabaletta Bio, Inc. has a one year low of $1.40 and a one year high of $4.23. The stock’s 50 day moving average price is $2.89 and its 200 day moving average price is $3.06.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03. On average, analysts forecast that Cabaletta Bio, Inc. will post -1.34 earnings per share for the current fiscal year.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.